Although our experiments in vitro and ex vivo suggested the possibility of its contribution to virulence, obvious differences in viability and health status were not observed between the mice infected with the wild-type and Cgatg1 strains
To assess the associations of semaglutide with incident AUD (first time diagnosis of AUD), the study population included 83,825 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new-user design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (naltrexone, topiramate, bupropion, orlistat, phentermine) 54 during 6/202112/2022 (time zero or index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Zepbound is a dual-agonist drug , meaning it works on two different receptors in the body GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), mimicking these two hormones
While experts lauded approval of Zepbound, they worried that it wouldnt necessarily mean greater access to the drug, which has been prescribed off-label to help people pare pounds